Furthermore, the occurrence of SETD2 (3p21) mutation was significantly higher in the NF2 loss than in the remaining uRCC tumours (44% versus 9%, Fisher's exact test, P=0.004). This evidence concerns the gene NF2 and Unclassified Renal Cell Carcinoma.